Law & Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law & Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
AMDL, Inc.
U.S. patent granted for its Immunogene therapy for cancer
June 26th, 2004
AMDL, Inc., (ADL), developer and marketer of tests for the early detection of cancer and other serious diseases, which recently announced that it had launched a major effort to seek a strategic partner for clinical trials, and eventual marketing, of its unique Combination Immunogene therapy (CIT), said the technology has received a United States Patent. CIT uses two genes in combination to build the body's immune system and to destroy cancer cells. The GM-CSF gene alters the tumor to activate tumor-specific T-cells within the immune system, while the B7-2 gene enters the tumor to stimulate larger and stronger T-cells to fight the cancer. This is a variation of the...
Source: Law & Health Weekly (2004-06-26)
|
